Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

Speciality: Hematology

Description:

A warm welcome to all the medical professionals in this cutting-edge session on the treatment of multiple myeloma. Today we'll discuss the groundbreaking findings on Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity. The goal of modern myeloma therapy is to achieve a deep and durable response, ideally leading to minimal residual disease (MRD) negativity, where highly sensitive tests can't detect any remaining cancer cells. The addition of daratumumab to the standard Rd regimen has shown a significant impact on this key endpoint.

The combination of daratumumab, an anti-CD38 monoclonal antibody, with lenalidomide and dexamethasone has demonstrated unprecedented rates of MRD negativity in clinical trials. This is a critical development because achieving MRD negativity is strongly correlated with extended progression-free survival (PFS) and overall survival (OS). The DRd regimen has not only prolonged PFS compared to Rd alone but has also deepened responses, leading to a much higher percentage of patients achieving complete remission and, most importantly, a state of MRD negativity.

Therefore, get an overall knowledge of how the DRd regimen is setting a new benchmark in multiple myeloma treatment by significantly improving MRD negativity rates. Listen to the webinar, absorb the shared knowledge on this practice-changing data, and follow Hidoc for more such indispensable sessions that are shaping the future of oncology.

See More Webinars @ Hidoc Webinars